SEC Form 4 · accession 0001019056-18-000418
Aptevo Therapeutics Inc. · APVO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey G. Lamothe
Officer — SVP, CFO and Treasurer
Period of report
Mar 1, 2018
Accepted (ET)
Mar 5, 2018 · 7:38 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001671584
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 1, 2018 | M | 7,320 | — | A | 66,429 | D | |
| Common Stock | Mar 1, 2018 | F | 1,717 | $3.04 | D | 64,712 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF1,F2 | — | Mar 1, 2018 | M | 7,320 | D | — | — | Common Stock | 7,320 | 14,065 | D |
Explanation of responses
- F1Each RSU converts into the Issuer's common stock on a one-for-one basis.
- F2The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on March 1, 2016. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016 (the "Spin-off"), each RSU was adjusted and assumed by the Issuer. The RSUs vest as follows: 7,320 on March 1, 2017, 7,320 on March 1, 2018 and 7,318 on March 1, 2019.